{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.13","upperLimit":"92.31","value":"80.13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"}],"units":"Participants"}],"description":"The percentage of time with an increase in platelet count ≥ 20 x 10⁹ cells/L above baseline from week 2 until the end of the treatment period without rescue medication use within the past 4 weeks.\n\nFor each participant, the percentage of time with an increase in platelet count ≥ 20 x10⁹ cells/L above baseline was calculated as the number of months the median platelet count was ≥ 20 x10⁹ cells/L above baseline divided by the total number of months assessed.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.","id":"OG000","title":"Romiplostim"}],"paramType":"MEDIAN","populationDescription":"Efficacy analysis set","reportingStatus":"POSTED","timeFrame":"Baseline and from week 2 to month 36","title":"Percentage of Time With an Increase in Platelet Count ≥ 20 x 10⁹ Cells/L Above Baseline","type":"SECONDARY","unitOfMeasure":"percentage of time"}